RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
Results from ongoing Phase III clinical trial announced
Read more »
Graphic designed by PATH
Partnering with us
We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.
Our portfolio
We maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.
What we do and how we do it
We provide funding and technical support to partners worldwide to accelerate the development of malaria vaccines. We also work to ensure that malaria vaccines will reach those who need them.
MVI and Inovio Pharmaceuticals to accelerate development of malaria vaccines and delivery technologies
Follow-on collaboration expected to lead to clinical trials.
Phase 3 trial of RTS,S/AS01 malaria vaccine in African infants
Results for children aged 6-12 weeks at first vaccination published in New England Journal of Medicine.
Community perceptions of malaria and vaccines in two districts of Mozambique
Article in Malaria Journal explores sociocultural and health communications issues among individuals at the community level who are responsible for decisions about vaccine use.
MVI collaborates with International AIDS Vaccine Initiative and Imperial College London
New central "reference" lab to standardize ability to measure performance of malaria vaccine formulations.
Tests find malaria vaccine useful
Article in The Washington Post on malaria vaccine being tested in seven African countries.
Twitter
Flickr